Insights

Recent Funding Allogene Therapeutics recently secured a $15 million grant from the California Institute for Regenerative Medicine to support the development of AlloCAR T investigational products. This funding injection indicates strong financial support and potential for further expansion in the biotechnology sector.

Strategic Partnerships The partnership formed between Allogene Therapeutics and Arbor Biotechnologies for CRISPR technology signifies a commitment to innovative research and development. Leveraging this collaboration can open doors to new technological advancements and market growth opportunities.

Industry Recognition Allogene Therapeutics being recognized in the Debt & Financing category highlights the company's presence and credibility in the industry. This recognition can be utilized to enhance brand reputation and attract potential investors or partners.

Market Expansion The CAR T Together initiative launched by Allogene Therapeutics aims to improve CAR T therapies through the development of allogeneic cell therapy options. This initiative presents a unique selling proposition for market expansion and competitive differentiation.

Investor Interest Notable investments from companies like Ucihealth and McGlone Suttner Wealth Management Inc. signify confidence in Allogene Therapeutics' potential for growth. Leveraging investor interest can lead to strategic alliances and further funding opportunities.

Allogene Therapeutics Tech Stack

Allogene Therapeutics uses 8 technology products and services including Databricks, OneTrust, Priority Hints, and more. Explore Allogene Therapeutics's tech stack below.

  • Databricks
    Big Data Processing
  • OneTrust
    Cookie Compliance
  • Priority Hints
    Performance
  • Hadoop
    Programming Languages
  • C#
    Programming Languages
  • New Relic
    Real User Monitoring
  • Autodesk
    Visualisation Software
  • Nginx
    Web Servers

Media & News

Allogene Therapeutics's Email Address Formats

Allogene Therapeutics uses at least 1 format(s):
Allogene Therapeutics Email FormatsExamplePercentage
first.last@allogene.comJohn.Doe@allogene.com
97%
last@allogene.comDoe@allogene.com
1%
fir.last@allogene.comJoh.Doe@allogene.com
1%
first@allogene.comJohn@allogene.com
1%

Frequently Asked Questions

Where is Allogene Therapeutics's headquarters located?

Minus sign iconPlus sign icon
Allogene Therapeutics's main headquarters is located at 210 E Grand Ave South San Francisco, California 94080 US. The company has employees across 3 continents, including North AmericaAsiaEurope.

What is Allogene Therapeutics's phone number?

Minus sign iconPlus sign icon
You can contact Allogene Therapeutics's main corporate office by phone at +1-650-457-2700. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Allogene Therapeutics's stock symbol?

Minus sign iconPlus sign icon
Allogene Therapeutics is a publicly traded company; the company's stock symbol is ALLO.

What is Allogene Therapeutics's official website and social media links?

Minus sign iconPlus sign icon
Allogene Therapeutics's official website is allogene.com and has social profiles on LinkedIn.

How much revenue does Allogene Therapeutics generate?

Minus sign iconPlus sign icon
As of July 2024, Allogene Therapeutics's annual revenue reached $75M.

What is Allogene Therapeutics's SIC code NAICS code?

Minus sign iconPlus sign icon
Allogene Therapeutics's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Allogene Therapeutics have currently?

Minus sign iconPlus sign icon
As of July 2024, Allogene Therapeutics has approximately 277 employees across 3 continents, including North AmericaAsiaEurope. Key team members include Chief Technology Officer: T. M.Chief People Officer: S. L.Vice President Clinical Operations: A. K.. Explore Allogene Therapeutics's employee directory with LeadIQ.

What industry does Allogene Therapeutics belong to?

Minus sign iconPlus sign icon
Allogene Therapeutics operates in the Biotechnology Research industry.

What technology does Allogene Therapeutics use?

Minus sign iconPlus sign icon
Allogene Therapeutics's tech stack includes DatabricksOneTrustPriority HintsHadoopC#New RelicAutodeskNginx.

What is Allogene Therapeutics's email format?

Minus sign iconPlus sign icon
Allogene Therapeutics's email format typically follows the pattern of . Find more Allogene Therapeutics email formats with LeadIQ.

How much funding has Allogene Therapeutics raised to date?

Minus sign iconPlus sign icon
As of July 2024, Allogene Therapeutics has raised $110M in funding. The last funding round occurred on May 13, 2024.

When was Allogene Therapeutics founded?

Minus sign iconPlus sign icon
Allogene Therapeutics was founded in 2017.
Allogene Therapeutics

Allogene Therapeutics

Biotechnology ResearchCalifornia, United States201-500 Employees

Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) products for cancer and autoimmune disease. 

For additional information on our guidelines, please visit www.allogene.com/news-center#community-guidelines

Please be aware that the FBI recently issued a warning about an increased number of fake job postings for remote work employment that target applicants' personally identifiable information. All approved Allogene Therapeutics positions are accessible via the Allogene Careers page at www.allogene.com/careers. 

Section iconCompany Overview

Headquarters
210 E Grand Ave South San Francisco, California 94080 US
Phone number
+1-650-457-2700
SIC Code
8733 - Noncommercial Research Organizations
Stock Symbol
ALLO
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2017
Employees
201-500

Section iconFunding & Financials

  • $110M

    Allogene Therapeutics has raised a total of $110M of funding over 5 rounds. Their latest funding round was raised on May 13, 2024.

  • $50M$100M

    Allogene Therapeutics's revenue is in the range of $50M$100M

Section iconFunding & Financials

  • $110M

    Allogene Therapeutics has raised a total of $110M of funding over 5 rounds. Their latest funding round was raised on May 13, 2024.

  • $50M$100M

    Allogene Therapeutics's revenue is in the range of $50M$100M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.